Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
Stephen C Bain,Ofri Mosenzon,Rosario Arechavaleta,Pawel Bogdański,Abdurrahman Comlekci,Agostino Consoli,Chaicharn Deerochanawong,Kathleen Dungan,Maria C Faingold,Michael E Farkouh,Denise R Franco,Jeppe Gram,Cristian Guja,Pankaj Joshi,Rachid Malek,Juan F Merino-Torres,Michael A Nauck,Sue D Pedersen,Wayne H-H Sheu,Robert J Silver,Cees J Tack,Nikhil Tandon,Ole K Jeppesen,Mette Strange,Mette Thomsen,Mansoor Husain
DOI: https://doi.org/10.1111/dom.13553
Abstract:Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. Materials and methods: PIONEER 6 is a multinational, randomized, placebo-controlled, double-blind trial in patients with type 2 diabetes at high risk of CV events (defined as being aged ≥50 years and having established CV disease [CVD] or moderate [stage 3] chronic kidney disease [CKD], or being aged ≥60 years with ≥1 other CV risk factor). Patients were randomized to once-daily oral semaglutide (up to 14 mg) or placebo added to standard of care. The primary composite endpoint is time to first occurrence of CV death or non-fatal myocardial infarction or non-fatal stroke. The primary hypothesis was to exclude an excess in CV risk with oral semaglutide by assessing non-inferiority versus placebo for the primary endpoint (non-inferiority margin of 1.8 for the upper boundary of the 95% confidence interval of the hazard ratio). PIONEER 6 is event-driven, with follow-up continuing until accrual of at least 122 primary outcome events. There is no pre-defined minimal duration. Results: Overall, 3183 patients have been enrolled (mean age 66.1 years, 31.6% females) in 214 sites across 21 countries. At baseline, the mean duration of diabetes was 14.9 years, mean glycated haemoglobin concentration was 66 mmol/mol (8.2%), and 84.6% of patients had established CVD/moderate CKD. Conclusions: PIONEER 6 will provide evidence regarding the CV safety of oral semaglutide in patients with type 2 diabetes and high CV risk.